AIFF Stock Overview
A medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Firefly Neuroscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.18 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$5.16 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| AIFF | US IT | US Market | |
|---|---|---|---|
| 7D | -26.8% | 3.3% | 3.1% |
| 1Y | n/a | 15.2% | 25.4% |
Return vs Industry: Insufficient data to determine how AIFF performed against the US IT industry.
Return vs Market: Insufficient data to determine how AIFF performed against the US Market.
Price Volatility
| AIFF volatility | |
|---|---|
| AIFF Average Weekly Movement | n/a |
| IT Industry Average Movement | 7.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AIFF's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AIFF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Jon Olsen | fireflyneuro.com |
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners.
Firefly Neuroscience, Inc. Fundamentals Summary
| AIFF fundamental statistics | |
|---|---|
| Market cap | US$49.66m |
| Earnings (TTM) | -US$4.11m |
| Revenue (TTM) | US$64.00k |
760.0x
P/S Ratio-11.8x
P/E RatioIs AIFF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIFF income statement (TTM) | |
|---|---|
| Revenue | US$64.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$64.00k |
| Other Expenses | US$4.18m |
| Earnings | -US$4.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -6,426.56% |
| Debt/Equity Ratio | -14.4% |
How did AIFF perform over the long term?
See historical performance and comparison